Stock Scorecard
Stock Summary for Sanofi (SNY) - $46.30 as of 4/19/2024 8:54:20 PM EST
Total Score
13 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SNY
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SNY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SNY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for SNY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for SNY
Financial Details for SNY
Company Overview |
|
|---|---|
| Ticker | SNY |
| Company Name | Sanofi |
| Country | USA |
| Description | Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 4/25/2024 |
Stock Price History |
|
| Last Day Price | 46.30 |
| Last Day Price Updated | 4/19/2024 8:54:20 PM EST |
| Last Day Volume | 3,254,020 |
| Average Daily Volume | 1,798,904 |
| 52-Week High | 55.72 |
| 52-Week Low | 42.63 |
| Last Price to 52 Week Low | 8.61% |
Valuation Measures |
|
| Trailing PE | 20.00 |
| Industry PE | 100.90 |
| Sector PE | 61.34 |
| 5-Year Average PE | 8.58 |
| Free Cash Flow Ratio | 13.27 |
| Industry Free Cash Flow Ratio | 12.64 |
| Sector Free Cash Flow Ratio | 30.17 |
| Current Ratio Most Recent Quarter | 1.27 |
| Total Cash Per Share | 3.49 |
| Book Value Per Share Most Recent Quarter | 59.17 |
| Price to Book Ratio | 1.44 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 2.52 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
| Total Shares Outstanding | 2,496,450,000 |
| Market Capitalization | 115,585,635,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 5/9/2024 |
| Last Dividend Amount | 1.90 |
| Current Dividend Amount | 2.04 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 3.94 |
| Trailing Annual Dividend Yield | 8.50% |
| Forward Annual Dividend Rate | 4.03 |
| Forward Annual Dividend Yield | 8.69% |
| 5-Year Dividend Payments Count | 7 |
| 3-Year Average Dividend Yield | 3.96% |
| 5-Year Average Dividend Yield | 3.77% |
| 1-Year Dividend Growth Rate Percentage | -7.04% |
| 3-Year Dividend Growth Rate Percentage | -0.75% |
| 5-Year Dividend Growth Rate Percentage | 2.23% |
| All-Time Dividend Growth Rate Percentage | 8.20% |
| Dividend Payout Ratio | 171.94% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 21.70% |
| Annual Earnings Growth | -35.49% |
| Reported EPS 12 Trailing Months | 2.29 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 5.77 |
| Net Income Twelve Trailing Months | 7,925,000,000 |
| Net Income Past Year | 5,400,000,000 |
| Net Income Prior Year | 8,371,000,000 |
| Quarterly Revenue Growth YOY | 2.90% |
| 5-Year Revenue Growth | 3.84% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 8,710,000,000 |
| Total Cash Past Year | 8,710,000,000 |
| Total Cash Prior Year | 12,736,000,000 |
| Net Cash Position Most Recent Quarter | -5,637,000,000 |
| Net Cash Position Past Year | -5,637,000,000 |
| Long Term Debt Past Year | 14,347,000,000 |
| Long Term Debt Prior Year | 14,857,000,000 |
| Total Debt Most Recent Quarter | 14,347,000,000 |
| Equity to Debt Ratio Past Year | 0.84 |
| Equity to Debt Ratio Most Recent Quarter | 0.84 |
| Total Stockholder Equity Past Year | 74,040,000,000 |
| Total Stockholder Equity Prior Year | 73,144,000,000 |
| Total Stockholder Equity Most Recent Quarter | 74,040,000,000 |
Options |
|
| Put/Call Ratio | 1.06 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.55 |
| MACD Signal | -0.31 |
| 20-Day Bollinger Lower Band | 44.59 |
| 20-Day Bollinger Middle Band | 48.24 |
| 20-Day Bollinger Upper Band | 51.89 |
| Beta | 0.45 |
| RSI | 36.54 |
| 50-Day SMA | 50.44 |
| 200-Day SMA | 45.96 |
System |
|
| Modified | 4/18/2024 11:56:34 AM EST |